Vosevi (Gilead Sciences, Inc.)
Welcome to the PulseAid listing for the Vosevi drug offered from Gilead Sciences, Inc.. This Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient],Hepatitis C Virus NS5A Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA],Hepatitis C Virus NS3/4A Protease Inhibitor [EPC],HCV NS3/4A Protease Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Gilead Sciences, Inc. |
| NON-PROPRIETARY NAME: | SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR |
| SUBSTANCE NAME: | SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient],Hepatitis C Virus NS5A Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA],Hepatitis C Virus NS3/4A Protease Inhibitor [EPC],HCV NS3/4A Protease Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-07-18 |
| END MARKETING DATE: | 0000-00-00 |
Vosevi HUMAN PRESCRIPTION DRUG Details:
| Item Description | Vosevi from Gilead Sciences, Inc. |
| LABELER NAME: | Gilead Sciences, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 400; 100; 100(mg/1; mg/1; mg/1) |
| START MARKETING DATE: | 2017-07-18 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 61958-2401_be390b03-e564-4753-a68a-5c108dcb49e5 |
| PRODUCT NDC: | 61958-2401 |
| APPLICATION NUMBER: | NDA209195 |
Other SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR Pharmaceutical Manufacturers / Labelers:
